During stages 1 and 2 , mean ALSFRS-R declined more slowly in participants who received 4 g ceftriaxone than in those on placebo ( difference 051 units per month , 95 % CI 002 to 100 ; p = 00416 ) , but in stage 3 functional decline between the treatment groups did not differ ( 009 , -006 to 024 ; p = 02370 ) .